Drug intelligence / Profile preview

ProT-096

Development stage: Preclinical
Lead developer: Protgen
Modality: Cell Therapies
Administration: Intravenous

Overview

ProT-096 is a personalized progenitor T cell therapy being developed by ProTgen. The therapy utilizes targeted Notch signaling pathway activators to generate progenitor T cells designed to reactivate the thymus and reconstitute the adaptive immune system. It is intended for the treatment of refractory leukemia and other hematologic malignancies in patients who have exhausted standard treatment options, aiming to provide long-term immune protection by addressing critical gaps in immune recovery.

Beyond the preview

Go deeper on ProT-096.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProT-096.

Explore the full profile